Sbir phase i: preclinical validation of an ocular antioxidant enhancing gene delivery vehicle to target dry macular degeneration
Ended Project Grant Awarded Last action
- Award ID
- 2111704
- Recipient
-
Oculogenex Inc. UEI K6P8KFEVG5D5
- Awarding agency
-
Division of Industrial Innovation
National Science Foundation
- Obligated
- $256,000
Award facts
- Assistance listing
- 47.041 Engineering
- Completion date
- Funding agency
- National Science Foundation
- Place of performance
- La Habra, CA 90631, USA
Award details come from USAspending.gov.
About this award
The National Science Foundation awarded Oculogenex a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) from May 1, 2021 to October 31, 2021. The grant funded Oculogenex's "Preclinical Validation of an Ocular Antioxidant Enhancing Gene Delivery Vehicle to Target Dry Macular Degeneration" project. Specifically, the grant supported Oculogenex's work to preclinically test a gene delivery method aimed at enhancing antioxidant levels to address dry macular degeneration. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research, consistent with the goals of this award to test an innovative ocular gene therapy approach.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $256,000 |
Quick answers
Who received award 2111704?
2111704 was awarded to Oculogenex Inc. by Division of Industrial Innovation (National Science Foundation) on May 1, 2021.
How much is award 2111704 worth?
$256,000 has been obligated on 2111704.
Which agency awarded 2111704?
Division of Industrial Innovation (National Science Foundation) awarded 2111704, with funding from National Science Foundation.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award